期刊文献+

RANKL、OPG、TRAIL在骨肉瘤中的表达及其临床意义 被引量:1

Expressions of RANKL,OPG and TRAIL in osteosarcoma
暂未订购
导出
摘要 目的探讨骨肉瘤组织中RANKL、OPG、TRAIL蛋白的表达情况。方法采用免疫组织化学SP法测定RANKL、OPG、TRAIL蛋白在50例骨肉瘤、20例骨软骨瘤中的表达。分析其在骨肉瘤、骨软骨瘤中表达差异及与骨肉瘤临床病理特征之间的关系。结果 OPG在骨肉瘤中的表达明显高于骨软骨瘤(P<0.01);TRAIL在骨肉瘤中的表达明显低于骨软骨瘤(P<0.01)。OPG、TRAIL的表达与Enneking临床分期有关(P<0.01)。结论 OPG、TRAIL是骨肉瘤发生、发展的标记之一。 Objective To investigate the expressions of RANKL,OPG and TRAIL in osteosarcoma.Methods Immunohistochemical staining method was used to evaluate the expressions of RANKL,OPG and TRAIL in 50 osteosarcoma specimens and 20 osteo-chondroma specimens.Results The positive rate of OPG expression in osteosarcoma was higher than that in osteochondroma (P<0.01) .The positive rate of TRAIL expression in osteosarcoma was lower than that in osteochondroma (P<0.01) .The positive rates of OPG and TRAIL had close relationship with Enneking clinical staging (P<0.01) .Conclusion OPG and TRAIL might be the markers of occurrence and progress of osteosarcoma.
出处 《临床军医杂志》 CAS 2010年第4期509-511,F0004,共4页 Clinical Journal of Medical Officers
  • 相关文献

参考文献3

  • 1刘耀明,周敏慧,张大富,程刚,贺云飞,徐崇宏,张彦博,李晓鸣.MMP-7、COX-2在骨肉瘤中的表达和临床病理意义[J].西北国防医学杂志,2009,30(4):280-282. 被引量:4
  • 2刘耀明,李晓鸣,程刚,贺云飞,伍红桦.PTEN与FHIT在骨肉瘤组织中的表达[J].中华肿瘤防治杂志,2006,13(19):1493-1495. 被引量:1
  • 3Ingunn Holen,Simon S. Cross,Helen L. Neville-Webbe,Neil A. Cross,Sabapathy P. Balasubramanian,Peter I. Croucher,C. Alyson Evans,Jennifer M. Lippitt,Robert E. Coleman,Colby L. Eaton. Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival?[J] 2005,Breast Cancer Research and Treatment(3):207~215

二级参考文献18

  • 1施红旗,张谷,楼善贤,刘庆伟.PTEN蛋白在前列腺癌中的表达和意义[J].肿瘤防治杂志,2004,11(10):1066-1068. 被引量:3
  • 2周旭,易继林,刘恩宇,郭悦青,李兴睿,刘谨文,杨志芳.PTEN基因在肝细胞肝癌中的表达及其意义[J].肿瘤防治杂志,2005,12(4):286-290. 被引量:6
  • 3Konno H, Baba M, Shoji T, et al. Cyclooxygenase - 2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer [ J ]. Clin Exp Metastasis, 2002,19 (6) :527 - 534.
  • 4Beeghly - Fadiel A, Shu XO, Long J, et al. Genetic polymorphisms in the MMP - 7 gene and breast cancer survival[ J]. Int J Cancer,2008,16( 1 ) :208 -214.
  • 5DickensD S, Cripe TP. Effect of combined cyclooxygenase - 2 and matrix metallop roteinase inhibition on human sarcoma xenografts [ J ]. J Pediatr Hematol Oncol, 2003,25 ( 9 ) : 709 -714.
  • 6Zhang X, Schwarz EM, Young DA,et al. Cyclooxygenase - 2 regulates mesenchymal cell differentiation into the osteoblast lineageand is critically involved in bone repair [ J ]. J Clin Invest ,2002,109 ( 11 ) : 1405 - 1415.
  • 7Brun JL, Cortez A, Commo F, et al. Serous and mucinous ovarian tumors express different profiles of MMP -2, -7, - 9, MT1 - MMP, and TIMP - 1and -2 [ J]. Int J Oncol, 2008,33 ( 6 ) : 1239 - 1246.
  • 8Yaginuma Y,Yamashita J,Ishiya T,et al.Abnormal structure and expression of PNET/MMACI gene in human uterine cancers[J].MOL Carcinog,2000,27(2):110-116.
  • 9Cairns P,Okami K,Halachmi S,et al.Frequent inactivation of PNET/MMACI in primary prostate cancer[J].Cancer Res,1997,57(22):4997-5000.
  • 10Levine R A,Forest T,Smith C.Tumor suppressor PTENis mutated in canine osteosarcoma cell line and tumors[J].Vet pathol,2002,39:372-378.

共引文献3

同被引文献16

  • 1Gniffith TS, Lynch DH. Trail: a molecule with multiple receptor and control mechanisms[J]. Curr Opin Immunol, 1998,10 (5) :559-63.
  • 2Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that in duces apoptosis[J]. Immunity, 1995,3(6) :673-82.
  • 3Spienings DC, de Vries EG, Vellenga E, et al. Tissue distribution of the death ligaand TRAIL and its receptors[J]. J Histochem Cytochem, 2004,52 (6): 821-31.
  • 4Chen Q, Ray S, Hussein MA, et al. Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma [J]. Leuk Lymphoma, 2003,44 (7) : 1209-14.
  • 5Kim Y, Seol DW. TRAIL, a mighty apoptosis inducer [J]. Mol Cells, 2003,15 ( 3 ) : 283-93.
  • 6Buchsbaum DJ, Zhou T, Lobuglio AF, et al. TRAIL receotortargeted therapy[J]. Future Oncol ,2006,2(4):493-508.
  • 7Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/ TRAIL dependent revruitment of endogenous FADD and easpase-8 to srath receptors 4 and 5 [J]. Irnmunity, 2000,12 (6):611-20.
  • 8Fukud M,Hamao A, Tanaka A, et al. Tumor necrosis factorrelated apoptosis-indueing ligand(TRAIL/APO2L) and its receptors expression in human squamous cell carcinoma of the oral eavity[J]. Oneol Rep, 2003,10(5) : 1113-9.
  • 9Arts HJ,de Jong S, Hollema H, et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma [J]. Gynecol Oncol, 2004,92 (3) : 794-800.
  • 10Cretney E, Takeda K, Smyth MJ. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand(TRAIL)/TRAIL receptor pathway[J]. Int J Biochem Cell Biol, 2007,39 (2) : 280-6.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部